Neurotrope, Inc. (NTRP) News

Neurotrope, Inc. (NTRP): $0.94

-0.11 (-10.48%)

POWR Rating

Component Grades













Add NTRP to Watchlist
Sign Up

Industry: Biotech


of NR

in industry

Filter NTRP News Items

NTRP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NTRP News From Around the Web

Below are the latest news stories about Neurotrope Inc that investors may wish to consider to help them evaluate NTRP as an investment opportunity.

Neurotrope secures supply of Bryostatin-1

Neurotrope (NTRP) inks an agreement with BryoLogyx to supply synthetic Bryostatin-1, manufactured by Albany Molecular Research, for its clinical trials in Alzheimer's disease and other neurodegenerative disorders and commercial use, if approved.BryoLogyx will pay a fee on its gross sales of Bryostatin-1 for the treatment of acute lymphocytic leukemia ((ALL))...

Seeking Alpha | June 10, 2020

BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1

DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1

Business Wire | June 10, 2020

Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia

Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced its entry into a strategic agreement with BryoLogyx Inc.,, for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. ("AMRI"), a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease ("AD") and other neurodegenerative diseases and, ultimately, as a source for potential commercial drug supply if regulatory approval is received.

Yahoo | June 10, 2020

Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease

Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health (NIH) under a $2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD. The Company has engaged Worldwide Clinical Trials to initiate site recruitment and activation.

Yahoo | May 28, 2020

IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - WMGI, MINI, NTRP

NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek ...

Yahoo | May 20, 2020

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. ("Neurotrope") will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. ("Petros"). Petros is expected to become a Nasdaq traded company focused solely on men's health conditions. Petros' cornerstone product would be Metuchen's Stendra® (avanafil) for erectile dysfunction ("ED"). Petros' pip...

Yahoo | May 18, 2020

Do Directors Own Neurotrope, Inc. (NASDAQ:NTRP) Shares?

We can readily understand why investors are attracted to unprofitable companies. For example, although made...

Yahoo | March 18, 2020

Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on

Benzinga | January 22, 2020

Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value. "Following the results from our Phase 2 study of Bryostatin-1 in Alzheimer's disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value," stated Dr. Charles S. Ryan, Neurotrope's Chief Executive Officer. There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome.

Yahoo | October 8, 2019

Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?

Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.

Yahoo | October 4, 2019

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5707 seconds.